LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Avatud

SektorTervishoid

99.68 -0.56

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

97.72

Max

101.39

Põhinäitajad
By Trading Economics
Sissetulek	64M 118M
Müük	-29M 377M
P/E Sektori keskmine	23.181 49.888
Aktsiakasum	1.46
Kasumimarginaal	31.383
Töötajad	1,193
EBITDA	-17M 81M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+5.99% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	609M 6.3B
Eelmine avamishind	100.24
Eelmine sulgemishind	99.68

Uudiste sentiment

By Acuity

50%

153 / 344 Pingereas Healthcare

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. juuni 2026, 23:45 UTC

Omandamised, ülevõtmised, äriostud

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. juuni 2026, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. juuni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. juuni 2026, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. juuni 2026, 20:51 UTC

Tulu

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. juuni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. juuni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. juuni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. juuni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. juuni 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. juuni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. juuni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. juuni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. juuni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. juuni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. juuni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. juuni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

5.99% tõus

12 kuu keskmine prognoos

Keskmine 106 USD 5.99%

Kõrge 115 USD

Madal 94 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

153 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.